CN103920097A - Pharmaceutical composition for treating chronic prostatitis - Google Patents
Pharmaceutical composition for treating chronic prostatitis Download PDFInfo
- Publication number
- CN103920097A CN103920097A CN201410175971.XA CN201410175971A CN103920097A CN 103920097 A CN103920097 A CN 103920097A CN 201410175971 A CN201410175971 A CN 201410175971A CN 103920097 A CN103920097 A CN 103920097A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- fructus
- radix
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating chronic prostatitis. The pharmaceutical composition comprises glossy privet fruits, herba portulacae, plantain herb, gardenia, wolfberry fruits, herba leonuri and the like. The pharmaceutical composition for treating the chronic prostatitis is reasonable in formula, aims at symptoms of the chronic prostatitis, is used for treating root causes as well as treating the urinary tract symptoms of the chronic prostatitis, has good effects of promoting blood circulation to remove blood stasis, diminishing inflammation, relieving pain, clearing away heat and toxic materials, regulating flow of qi, guiding stasis and removing water to treat stranguria, and also has the effects of enhancing the immunity of a human body and resisting regeneration of bacteria.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of pharmaceutical composition for the treatment of chronic prostatitis.
Background technology
Chronic prostatitis is male urinary system common disease, pathogenic factor and pathogenesis more complicated, and clinical symptoms is more, is difficult to healing, and easily recurrence, and becomes Urology Surgery doctor's a thorny difficult problem.Mostly its cause of disease of opinion, be by damp invasion of lower energizer, due to functioning of bladder is unfavorable.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of chronic prostatitis.
In order to realize object of the present invention, the invention provides a kind of pharmaceutical composition for the treatment of chronic prostatitis, the crude drug that it comprises following weight portion: Fructus Ligustri Lucidi 10-30 part, Herba Portulacae 20-50 part, Herba Plantaginis 10-30 part, Flos micheliae Albae 1-20 part, Fructus Lycii 10-30 part, Herba Leonuri 10-30 part, Fructus Schisandrae Chinensis 10-30 part, Semen Cuscutae 10-30 part, Elatostema oblohgifolium Fu. (Elatostema bodinier Levl) 10-30 part, Radix Astragali 10-30 part, Cortex Phellodendri 10-30 part and Rhizoma Curcumae 1-20 part.
Preferably, the crude drug that the pharmaceutical composition for the treatment of chronic prostatitis of the present invention comprises following weight portion: 10 parts of 15 parts of Fructus Ligustri Lucidi, 30 parts of Herba Portulacaes, 20 parts of Herba Plantaginiss, 10 parts of Flos micheliae Albae, 20 parts of Fructus Lycii, 25 parts of Herba Leonuris, 15 parts of Fructus Schisandrae Chinensis, 20 parts of Semen Cuscutae, 15 parts of Elatostema oblohgifolium Fu. (Elatostema bodinier Levl), 20 parts of the Radixs Astragali, 15 parts of Cortex Phellodendris and Rhizoma Curcumae.
More preferably, the pharmaceutical composition for the treatment of chronic prostatitis of the present invention also comprises the crude drug of following weight portion: Rhizoma Polygoni Cuspidati 10-20 part, Radix Campylotropis Hirtella (Herba Myrsines Africanae) 1-20 part, Radix Paeoniae Alba 10-30 part, Pericarpium Citri Reticulatae 10-20 part, Herba Linderniae ruellioidis 1-20 part, Radix Polygalae 1-20 part, Fructus Cnidii 1-10 part, Herba Hedyotidis Diffusae 1-10 part, Fructus Corni 1-20 part, Fructus Rubi 1-10 part, Ganoderma 1-10 part, Radix Angelicae Sinensis 10-30 part, Flos Lonicerae 1-20 part, Radix Pulsatillae 1-10 part, Cortex Eucommiae 1-20 part and Stamen Nelumbinis 1-10 part.
Most preferably, the pharmaceutical composition for the treatment of chronic prostatitis of the present invention also comprises the crude drug of following weight portion: 6 parts of 12 parts of Rhizoma Polygoni Cuspidati, 10 parts of Radix Campylotropis Hirtella (Herba Myrsines Africanae)s, 20 parts of the Radix Paeoniae Albas, 15 parts of Pericarpium Citri Reticulataes, 8 parts of Herba Linderniae ruellioidiss, 10 parts of Radix Polygalaes, 8 parts of Fructus Cnidiis, 5 parts of Herba Hedyotidis Diffusaes, 10 parts of Fructus Corni, 8 parts of Fructus Rubies, 6 parts of Ganodermas, 20 parts of Radix Angelicae Sinensis, 10 parts of Flos Loniceraes, 8 parts of the Radix Pulsatillaes, 10 parts of the Cortexs Eucommiae and Stamen Nelumbiniss.
Preferably, described pharmaceutical composition is tablet, dispersible tablet, disintegrating tablet, instant, enteric coatel tablets, capsule or decoction.
In the present invention:
Radix Campylotropis Hirtella (Herba Myrsines Africanae)
Base is former: the young platymiscium ferrum of Myrsinacea ferrum son's root or branch and leaf
Former plant: the young myrsine africana of ferrum L.
Herba Linderniae ruellioidis
Base is former: the herb of the long capsule Herba Linderniae Crustaceae of Scrophulariaceae Vandellia plant
Former plant: long capsule Herba Linderniae Crustaceae Lindernia anagallis (Burm.f.) Pennell[L.cordifolia (Colsm.) Merr.]
In compositions of the present invention, Herba Linderniae ruellioidis, Radix Campylotropis Hirtella (Herba Myrsines Africanae) are monarch drug; Rhizoma Polygoni Cuspidati, Herba Plantaginis, Fructus Schisandrae Chinensis, Fructus Corni, the Cortex Eucommiae, Fructus Ligustri Lucidi, the Radix Pulsatillae, Radix Angelicae Sinensis, Semen Cuscutae are ministerial drug; The Radix Paeoniae Alba, the Radix Astragali, Flos Lonicerae, Radix Polygalae, Flos micheliae Albae, Fructus Lycii, Fructus Cnidii, Herba Hedyotidis Diffusae, Stamen Nelumbinis, Herba Leonuri, Herba Portulacae, Fructus Rubi are adjuvant drug; Pericarpium Citri Reticulatae, Ganoderma, Elatostema oblohgifolium Fu. (Elatostema bodinier Levl), Cortex Phellodendri and Rhizoma Curcumae are for making medicine.The reasonable recipe of the pharmaceutical composition for the treatment of chronic prostatitis of the present invention, for chronic prostatitis disease, when manifesting, its urinary tract symptom for the treatment of effects a permanent cure especially, for prostate, play good blood circulation promoting and blood stasis dispelling, anti-inflammatory analgetic, heat-clearing and toxic substances removing, circulation of qi promoting intestinal stasis relieving, relieving stranguria by diuresis effect, increase body immunity, opposing bacteriological aftergrowth simultaneously.
The specific embodiment
Below by embodiment, further illustrate the present invention.It should be understood that embodiments of the invention are for the present invention rather than limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent otherwise in the present invention is percetage by weight.
Embodiment decoction of the present invention
Get 15 grams of Fructus Ligustri Lucidi, 30 grams of Herba Portulacaes, 20 grams of Herba Plantaginiss, 10 grams of Flos micheliae Albae, 20 grams of Fructus Lycii, 25 grams of Herba Leonuris, 15 grams of Fructus Schisandrae Chinensis, 20 grams of Semen Cuscutae, 15 grams of Elatostema oblohgifolium Fu. (Elatostema bodinier Levl), 20 grams of the Radixs Astragali, 15 grams of Cortex Phellodendris, 10 grams of Rhizoma Curcumae, 12 grams of Rhizoma Polygoni Cuspidati, 10 grams of Radix Campylotropis Hirtella (Herba Myrsines Africanae)s, 20 grams of the Radix Paeoniae Albas, 15 grams of Pericarpium Citri Reticulataes, 8 grams of Herba Linderniae ruellioidiss, 10 grams of Radix Polygalaes, 8 grams of Fructus Cnidiis, 5 grams of Herba Hedyotidis Diffusaes, 10 grams of Fructus Corni, 8 grams of Fructus Rubies, 6 grams of Ganodermas, 20 grams of Radix Angelicae Sinensis, 10 grams of Flos Loniceraes, 8 grams of the Radix Pulsatillaes, 6 grams of 10 grams of the Cortexs Eucommiae and Stamen Nelumbiniss, add 2000 milliliters, water, in being housed, at 100 ℃, heats 5 hours by the flask of condenser, filter, filtrate is decoction of the present invention.
Experimental example
From in December, 2011-2013, the court accepts 96 routine patients with chronic prostatitis for medical treatment year October in selection, age 19-48 year, average (35 ± 3.89) year; Course of disease 2-30 month, average (16 ± 2.72) individual month.According to medical order, be divided into matched group 48 example and treatment group 48 examples, 2 groups of patients no difference of science of statistics (P>0.05) on age, the course of disease, severe extent, has comparability.
Diagnostic criteria
Diagnostic criteria is according to the diagnostic criteria to chronic prostatitis in < < China Urology Surgery 2007 guide > > of association: 1. paruria: frequent micturition in various degree, urgent micturition, dysurea, there is residual urine sense, urethra scorching hot is uncomfortable, or urethra nebulousurine.2. local pain: perineum genital area, hypogastric region suprapubic region, waist sacral region or anus be falling inflation pain around.3. rectal touch: lay one's hand on and body of gland full, have tenderness; Body of gland quality is harder, or nodosity; Body of gland can increase, normal or dwindle.4. EPS microscopy: WBC >=10/Hp; Lecithin reduces or disappears.5. prostatic fluid antibacterial culturing is negative.
Exclusion standard merges other acute illnesss, prostatic hyperplasia, urethral stricture, tumor of prostate, cardiovascular, brain, liver, kidney and hemopoietic system serious disease, psychosis, chronic diarrhea etc.
Data all represent with percentage ratio, test front and back data and carry out statistical procedures with SPSS11.5 software.Measurement data is relatively with t check, and enumeration data is checked with X.
The decoction making in the oral embodiment for the treatment of group is treated, and one day twice, each oral 100 milliliters, treats continuously 3 weeks.
Matched group Oral Administration of Norfloxacin capsule (Tianjin Central Pharmaceutical Co., Ltd), 1 0.4g (4), l day 2 times, continuous 3 weeks.
During treatment, 2 groups are not all used other treatment method.After treatment finishes, row EPS is conventional, NIH Symptom of Chronic Prostatitis carries out curative effect evaluation.
Curative effect determinate standard
With reference to National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scoring and EPS-WBC counting, measure.Cure: syndrome scoring reduces >90% before treatment, and WBC<10/HP; Effective: syndrome scoring reduces 60%-90% before treatment, and WBC treats front minimizing 50%-89% or WBC<15/HP; Effective: syndrome scoring reduces 30%-59% before treatment, and WBC treats front minimizing 25%-49%; Invalid: syndrome scoring reduces <30% before treatment, or WBC treats front minimizing <25%.
Result
Through treatment, before and after 2 groups of treatments, TCM syndrome evaluation is relatively in Table 1.
Tcm syndrome integral contrast before and after 2 groups of treatments of table 1
With this group before treatment,
△p < 0.01; With comparison after treatment of control group,
*p < 0.05
2 groups of Clinical efficacy comparisons are in Table 2.
2 groups of Clinical efficacy comparison examples of table 2 (%)
With matched group comparison,
*p < 0.05.
Claims (5)
1. a pharmaceutical composition for the treatment of chronic prostatitis, it is characterized in that the crude drug that it comprises following weight portion: Fructus Ligustri Lucidi 10-30 part, Herba Portulacae 20-50 part, Herba Plantaginis 10-30 part, Flos micheliae Albae 1-20 part, Fructus Lycii 10-30 part, Herba Leonuri 10-30 part, Fructus Schisandrae Chinensis 10-30 part, Semen Cuscutae 10-30 part, Elatostema oblohgifolium Fu. (Elatostema bodinier Levl) 10-30 part, Radix Astragali 10-30 part, Cortex Phellodendri 10-30 part and Rhizoma Curcumae 1-20 part.
2. the pharmaceutical composition for the treatment of chronic prostatitis according to claim 1, it is characterized in that the crude drug that it comprises following weight portion: 10 parts of 15 parts of Fructus Ligustri Lucidi, 30 parts of Herba Portulacaes, 20 parts of Herba Plantaginiss, 10 parts of Flos micheliae Albae, 20 parts of Fructus Lycii, 25 parts of Herba Leonuris, 15 parts of Fructus Schisandrae Chinensis, 20 parts of Semen Cuscutae, 15 parts of Elatostema oblohgifolium Fu. (Elatostema bodinier Levl), 20 parts of the Radixs Astragali, 15 parts of Cortex Phellodendris and Rhizoma Curcumae.
3. the pharmaceutical composition for the treatment of chronic prostatitis according to claim 1 and 2, it is characterized in that, it also comprises the crude drug of following weight portion: Rhizoma Polygoni Cuspidati 10-20 part, Radix Campylotropis Hirtella (Herba Myrsines Africanae) 1-20 part, Radix Paeoniae Alba 10-30 part, Pericarpium Citri Reticulatae 10-20 part, Herba Linderniae ruellioidis 1-20 part, Radix Polygalae 1-20 part, Fructus Cnidii 1-10 part, Herba Hedyotidis Diffusae 1-10 part, Fructus Corni 1-20 part, Fructus Rubi 1-10 part, Ganoderma 1-10 part, Radix Angelicae Sinensis 10-30 part, Flos Lonicerae 1-20 part, Radix Pulsatillae 1-10 part, Cortex Eucommiae 1-20 part and Stamen Nelumbinis 1-10 part.
4. the pharmaceutical composition for the treatment of chronic prostatitis according to claim 4, it is characterized in that, it also comprises the crude drug of following weight portion: 6 parts of 12 parts of Rhizoma Polygoni Cuspidati, 10 parts of Radix Campylotropis Hirtella (Herba Myrsines Africanae)s, 20 parts of the Radix Paeoniae Albas, 15 parts of Pericarpium Citri Reticulataes, 8 parts of Herba Linderniae ruellioidiss, 10 parts of Radix Polygalaes, 8 parts of Fructus Cnidiis, 5 parts of Herba Hedyotidis Diffusaes, 10 parts of Fructus Corni, 8 parts of Fructus Rubies, 6 parts of Ganodermas, 20 parts of Radix Angelicae Sinensis, 10 parts of Flos Loniceraes, 8 parts of the Radix Pulsatillaes, 10 parts of the Cortexs Eucommiae and Stamen Nelumbiniss.
5. according to the pharmaceutical composition of the treatment chronic prostatitis described in any one in claim 1 to 4, it is characterized in that, described pharmaceutical composition is tablet, dispersible tablet, disintegrating tablet, instant, enteric coatel tablets, capsule or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410175971.XA CN103920097A (en) | 2014-04-29 | 2014-04-29 | Pharmaceutical composition for treating chronic prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410175971.XA CN103920097A (en) | 2014-04-29 | 2014-04-29 | Pharmaceutical composition for treating chronic prostatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103920097A true CN103920097A (en) | 2014-07-16 |
Family
ID=51138639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410175971.XA Pending CN103920097A (en) | 2014-04-29 | 2014-04-29 | Pharmaceutical composition for treating chronic prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103920097A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362510A (en) * | 2015-11-27 | 2016-03-02 | 苏州枫灵医药科技有限公司 | Chronic prostatitis treatment medicine |
| CN105816779A (en) * | 2016-05-12 | 2016-08-03 | 广西邦琪药业集团有限公司 | Medicine composition for treating chronic prostatitis |
| EP3257517A1 (en) * | 2016-06-15 | 2017-12-20 | Dai-Ming Kuo | The pharmaceutical composition for decreasing the side effects of cancer drug, and manufacturing method and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988675A (en) * | 2012-12-28 | 2013-03-27 | 青岛华仁信息技术开发有限公司 | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof |
| CN103550676A (en) * | 2013-09-24 | 2014-02-05 | 王兵 | Traditional Chinese medicine for treating chronic prostatitis |
| CN103599323A (en) * | 2013-11-13 | 2014-02-26 | 崔合芳 | Traditional Chinese medicinal composition for treating prostatitis |
-
2014
- 2014-04-29 CN CN201410175971.XA patent/CN103920097A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988675A (en) * | 2012-12-28 | 2013-03-27 | 青岛华仁信息技术开发有限公司 | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof |
| CN103550676A (en) * | 2013-09-24 | 2014-02-05 | 王兵 | Traditional Chinese medicine for treating chronic prostatitis |
| CN103599323A (en) * | 2013-11-13 | 2014-02-26 | 崔合芳 | Traditional Chinese medicinal composition for treating prostatitis |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362510A (en) * | 2015-11-27 | 2016-03-02 | 苏州枫灵医药科技有限公司 | Chronic prostatitis treatment medicine |
| CN105816779A (en) * | 2016-05-12 | 2016-08-03 | 广西邦琪药业集团有限公司 | Medicine composition for treating chronic prostatitis |
| EP3257517A1 (en) * | 2016-06-15 | 2017-12-20 | Dai-Ming Kuo | The pharmaceutical composition for decreasing the side effects of cancer drug, and manufacturing method and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101700358B (en) | Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN102228603B (en) | Chinese medicine for treating retention of urine | |
| CN103920097A (en) | Pharmaceutical composition for treating chronic prostatitis | |
| CN102008569B (en) | Traditional Chinese medicine preparation for treating chronic prostatitis | |
| CN101455772B (en) | Preparation method of traditional Chinese medicine for treating gastric heat type acute mastitis | |
| CN103845617B (en) | One treats invisible brightic medicament | |
| CN102973715A (en) | Traditional Chinese medicine composition for treating astriction after being orally taken | |
| CN105148135A (en) | Traditional Chinese medicine preparation for treating chronic prostatitis | |
| CN102988788A (en) | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and clysis nursing method | |
| CN102335367A (en) | Medicine for treating pelvic inflammation | |
| CN104548048A (en) | Traditional Chinese medicine composition for treating rheumatic tendon and bone diseases | |
| CN104815198A (en) | Traditional Chinese medicinal decoction for treating diabetes | |
| CN104524432A (en) | Traditional Chinese medicine for treating liver and gallbladder damp-heat-type gallstone | |
| CN103845610A (en) | Medicament for treating prostatitis | |
| CN104491297B (en) | A kind of Chinese medicine composition for treating palindromic urinary tract infection | |
| CN102228643A (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN102824471B (en) | Traditional Chinese medicine drug for treating spinal disc herniation, sciatica and leg pain | |
| CN101167829B (en) | Traditional Chinese medicinal composition and enema for treating chronic colitis and preparation method thereof | |
| CN102813858B (en) | Traditional Chinese medicine for treating postpartum flooding by tonifying middle-jiao and vital energy | |
| CN105147971A (en) | Traditional Chinese medicine preparation for treating infantile suppurative tonsillitis | |
| CN104306936A (en) | Composition for treating chronic urticaria | |
| CN105012470A (en) | Medicine liquor for treating cervical cancer complication radiation proctitis through coloclysis | |
| CN103830684A (en) | Pharmaceutical composition for curing hypermenorrhea and application thereof | |
| CN103007242B (en) | Medicament for treating chronic prostatitis | |
| CN104383478A (en) | Traditional Chinese medicine for treating stomach cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140716 |